Zacks: Brokerages Expect Opko Health Inc. (NASDAQ:OPK) to Announce -$0.09 EPS

Brokerages expect that Opko Health Inc. (NASDAQ:OPK) will announce earnings of ($0.09) per share for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Opko Health’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.10). Opko Health posted earnings of ($0.14) per share during the same quarter last year, which would indicate a positive year over year growth rate of 35.7%. The company is scheduled to issue its next quarterly earnings report on Tuesday, May 5th.

On average, analysts expect that Opko Health will report full year earnings of ($0.36) per share for the current year, with EPS estimates ranging from ($0.39) to ($0.32). For the next year, analysts expect that the business will post earnings of ($0.31) per share, with EPS estimates ranging from ($0.40) to ($0.26). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Opko Health.

A number of equities analysts have recently issued reports on OPK shares. BidaskClub upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. ValuEngine upgraded shares of Opko Health from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Piper Sandler upped their target price on shares of Opko Health from to in a research report on Tuesday, March 10th. Finally, Barrington Research reiterated a “buy” rating and set a $4.00 target price on shares of Opko Health in a research report on Thursday, February 27th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $2.88.

In other Opko Health news, CEO Phillip Md Et Al Frost acquired 200,000 shares of the business’s stock in a transaction that occurred on Thursday, March 26th. The shares were acquired at an average cost of $1.38 per share, for a total transaction of $276,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $4,235,152.38. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have bought 1,537,501 shares of company stock worth $2,296,859 over the last quarter. 42.25% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OPK. Great West Life Assurance Co. Can acquired a new position in Opko Health during the fourth quarter valued at approximately $35,000. 360 Financial Inc. acquired a new stake in Opko Health in the fourth quarter worth $47,000. Sowell Financial Services LLC acquired a new stake in Opko Health in the fourth quarter worth $59,000. Alpine Global Management LLC bought a new position in shares of Opko Health during the fourth quarter worth $61,000. Finally, Hollencrest Capital Management bought a new position in shares of Opko Health during the fourth quarter worth $65,000. Institutional investors and hedge funds own 26.28% of the company’s stock.

Shares of OPK stock traded up $0.02 during trading hours on Monday, reaching $1.40. 11,474,535 shares of the company were exchanged, compared to its average volume of 31,235,914. Opko Health has a fifty-two week low of $1.33 and a fifty-two week high of $2.91. The stock’s fifty day moving average is $1.63 and its two-hundred day moving average is $1.68. The company has a market cap of $924.36 million, a price-to-earnings ratio of -2.64 and a beta of 1.99. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.30 and a quick ratio of 1.09.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Further Reading: Insider Trading – What You Need to Know

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.